Scholars@Duke publication: Liver Directed AAV Gene Therapy Reverses Progression of Glycogen Storage Disease Type IX γ2 in Mice

Liver Directed AAV Gene Therapy Reverses Progression of Glycogen Storage Disease Type IX γ2 in Mice

Publication , Conference

Gibson, RA; Lim, J-A; Choi, SJ; Koch, RL; Bali, D; Young, S; Jeck, W; Sun, B; Asokan, A; Kishnani, PS

Published in: MOLECULAR THERAPY

2022

MOLECULAR THERAPY

1525-0024

1525-0016

2022

478 / 479

APA

Chicago

ICMJE

MLA

NLM

Gibson, R. A., Lim, J.-A., Choi, S. J., Koch, R. L., Bali, D., Young, S., … Kishnani, P. S. (2022). Liver Directed AAV Gene Therapy Reverses Progression of Glycogen Storage Disease Type IX γ2 in Mice. In MOLECULAR THERAPY (Vol. 30, pp. 478–479).

Gibson, Rebecca A., Jeong-A Lim, Su Jin Choi, Rebecca L. Koch, Deeksha Bali, Sarah Young, William Jeck, Baodong Sun, Aravind Asokan, and Priya S. Kishnani. “Liver Directed AAV Gene Therapy Reverses Progression of Glycogen Storage Disease Type IX γ2 in Mice.” In MOLECULAR THERAPY, 30:478–79, 2022.

Gibson RA, Lim J-A, Choi SJ, Koch RL, Bali D, Young S, et al. Liver Directed AAV Gene Therapy Reverses Progression of Glycogen Storage Disease Type IX γ2 in Mice. In: MOLECULAR THERAPY. 2022. p. 478–9.

Gibson RA, Lim J-A, Choi SJ, Koch RL, Bali D, Young S, Jeck W, Sun B, Asokan A, Kishnani PS. Liver Directed AAV Gene Therapy Reverses Progression of Glycogen Storage Disease Type IX γ2 in Mice. MOLECULAR THERAPY. 2022. p. 478–479.

MOLECULAR THERAPY

1525-0024

1525-0016

2022

478 / 479